These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 313689)

  • 1. Circulating human T cell subset with a reversible E-rossetting capacity in cancer and normals-hypothesis on the regulatory mechanism influencing their role in CMI.
    Moroz C; Kupfer B; Giler S
    Adv Exp Med Biol; 1979; 114():733-8. PubMed ID: 313689
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of levamisole on peripheral T-lymphocytes of patients with malignant lymphomas.
    Sansoni P; Rossetti A; Tridente G; Butturini U
    J Immunopharmacol; 1982-1983; 4(3):223-32. PubMed ID: 6985219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tet60 and Tet18h rosette tests in breast cancer or Hodgkin's disease and in healthy persons].
    Gasińska A; Smolak K
    Nowotwory; 1980; 30(2):161-6. PubMed ID: 6968061
    [No Abstract]   [Full Text] [Related]  

  • 4. Action of levamisole on E-rosette forming cells and serum adenosine deaminase in Hodgkin's disease.
    Di Perri T; Auteri A; Laghi Pasini F; Mattioli F; Volpi L
    J Immunopharmacol; 1979; 1(2):233-46. PubMed ID: 553110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference of levamisole with inhibition of E-rosette formation by Hodgkin's disease and systemic lupus erythematosus cytotoxic sera.
    Del Giacco GS; Tognella S; Leone AL; Locci F; Cornaglia P; Sangiuolo A; Grifoni V
    Blood; 1979 May; 53(5):1002-6. PubMed ID: 435634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of levamisole, thymic humoral factor and indomethacin on e-rosette formation of lymphocytes in Hodgkin's disease.
    Ramot B; Rosenthal E; Biniaminov M; Ben-Bassat I
    Isr J Med Sci; 1981 Apr; 17(4):232-5. PubMed ID: 7195385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressor cel activity of ferritin-bearing lymphocytes in patients with breast cancer.
    Moroz C; Kupfer B
    Isr J Med Sci; 1981; 17(9-10):879-81. PubMed ID: 6458580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short term follow up study on non-specific modulation of CMI by levamisole in advanced breast cancer.
    Saha K; Madan R; Kapila H; Shinghal RN
    Indian J Med Res; 1985 May; 81():499-507. PubMed ID: 3875554
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of breast tumor antigen-sensitive circulating T-lymphocytes by antigen-stimulated active rosette formation.
    Ramey WG; Hashim GA; Burrows WB; Swistel AJ; Munther A; Fitzpatrick HF
    Cancer Res; 1979 Dec; 39(12):4796-801. PubMed ID: 315272
    [No Abstract]   [Full Text] [Related]  

  • 11. The significance of ferritin in malignant diseases.
    Giler S; Moroz C
    Biomedicine; 1978; 28(4):203-6. PubMed ID: 737272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of levamisole on the activity of the blood T-lymphocytes and of factors they produce in patients with laryngeal cancer].
    Volosevich LI; Lukach EV; Krivokhatskaia LD
    Eksp Onkol; 1988; 10(3):54-7. PubMed ID: 2970382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of surface markers of lymphocytes and their relation to suppressor function in lymphogranulomatosis].
    Tabagari DZ; Chernovskaia EM; Kadagidze ZG
    Eksp Onkol; 1985; 7(2):60-4. PubMed ID: 3159562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunity and hypersensitivity in Hodgkin's lymphoma].
    Leoni P; Marchegiani G; Montillo M; Centurioni R; Montroni M; Danieli G
    Minerva Med; 1982 May; 73(20):1361-9. PubMed ID: 6210855
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of thymosin on T-lymphocyte rosette formation in Nigerian patients with different types of cancer.
    Olusi SO; Oluwole SF; Odesanmi WO
    Afr J Med Med Sci; 1984; 13(3-4):103-9. PubMed ID: 6099969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease.
    Ramot B; Biniaminov M; Shoham C; Rosenthal E
    N Engl J Med; 1976 Apr; 294(15):809-11. PubMed ID: 1082545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of levamisole on E-rosette formation by trypsinized lymphocytes.
    Lomnitzer R; Rabson AR
    Clin Exp Immunol; 1978 Sep; 33(3):499-502. PubMed ID: 310743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immunity in early human breast carcinoma.
    Conesa LC; Pasqualini RS; Pujato D; Lynch M
    Cell Mol Biol Incl Cyto Enzymol; 1979; 24(4):355-61. PubMed ID: 387244
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of the E-rosette formation of T-lymphocytes by aggregated human IgG and restoration by levamisole.
    De Cock W; De Cree J; Verhaegen H
    Immunology; 1978 Aug; 35(2):223-7. PubMed ID: 312252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferritin and depressed lymphocytes in breast cancer.
    Whitehead RH; Roberts GP; Worwood M
    N Engl J Med; 1978 Feb; 298(5):280. PubMed ID: 304178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.